There have been a flurry of studies incl. meta-analysis that the anti-viral Remdesivir either only reduces hospital length of stay, impacts mortality only marginally, or does nothing at all. Is Remdesivir not for all COVID-19 patients though? Join us on a tour de force through the evidence!

Speaker: Rajesh T. Gandhi, MD (Massachusetts General Hospital/Harvard Medical School)

0:00 Intro

1:42 RDV background

4:07 Clinical Data

26:28 Does RDV work? Dr. Gandhi's take

27:36 Q&A

46:17 Outro

Trials mentioned:

-PINETREE https://doi.org/10.1056/nejmoa2116846

-ACCT-1 https://doi.org/10.1056/nejmoa2007764

-Solidarity https://doi.org/10.1016/s0140-6736(22)00519-0

-CATCO https://doi.org/10.1503/cmaj.211698

-GS-US-540-5774 https://doi.org/10.1001/jama.2020.16349

-Meta-anlysis by Lee et al. CMI 2022: https://doi.org/10.1016/j.cmi.2022.04.018

Hosted on Acast. See acast.com/privacy for more information.